$3.10
-0.10-3.13%
Ult. Agg.: Oct 16, 4:00 PM
$3.10
-0.10-3.13%
Relmada Therapeutics (RLMD) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.20 | $-0.19 | $-0.14 | $-0.04 |
| Actual | $-0.11 | $-0.22 | $-0.27 | $-0.30 |
| Surprise | +45.0% | -15.8% | -92.9% | -650.0% |
| Revenue | ||||
| Estimate | — | — | — | — |
| Actual | $0 | $0 | — | $0 |
| Surprise | — | — | — | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.14 | $-0.16 | $-0.17 | $-0.19 |
| Revenue | ||||
| Consensus | — | — | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.11 | $-0.20 | 45.0 % |
| Q1 | May 12, 2026 | $-0.22 | $-0.19 | -15.8 % |
| Q4 | Mar 19, 2026 | $-0.27 | $-0.14 | -92.9 % |
| Q3 | Nov 13, 2025 | $-0.30 | $-0.04 | -650.0 % |